APA (7th ed.) Citation

Kometas, M. L., Hoff, F. W., Hyak, J., Irizarry-Gatell, V., Marinos Velarde, A., Jackson, C., . . . Madanat, Y. F. (2025). Real world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS); a single center study in a heavily pretreated cohort. Leukemia & Lymphoma, 66(7), 1245. https://doi.org/10.1080/10428194.2025.2470783

Chicago Style (17th ed.) Citation

Kometas, Marisa L., et al. "Real World Efficacy of Luspatercept in Patients with Lower-risk Myelodysplastic Syndromes/neoplasms (MDS); a Single Center Study in a Heavily Pretreated Cohort." Leukemia & Lymphoma 66, no. 7 (2025): 1245. https://doi.org/10.1080/10428194.2025.2470783.

MLA (9th ed.) Citation

Kometas, Marisa L., et al. "Real World Efficacy of Luspatercept in Patients with Lower-risk Myelodysplastic Syndromes/neoplasms (MDS); a Single Center Study in a Heavily Pretreated Cohort." Leukemia & Lymphoma, vol. 66, no. 7, 2025, p. 1245, https://doi.org/10.1080/10428194.2025.2470783.